GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a continuous glucose monitoring (CGM)-based study
Main finding · CGM metrics during Ramadan, BB+ vs BBResult — go to the resultReduction in incremental post-iftar AUC ≈61 %Authors' conclusion
In matched insulin-treated type 2 diabetes cohorts, add-on semaglutide or tirzepatide stabilised Ramadan glycaemia and reduced post-iftar hyperglycaemia without increasing hypoglycaemia, and was well tolerated with no treatment discontinuations during Ramadan.
Study context
- Population
- Adults with T1D or T2D using FreeStyle Libre CGM who completed ≥ 14 full fasting days during Ramadan 2025140 screened
- Participants
- 54 adults
- Exposure
- Basal-bolus insulin plus tirzepatide or semaglutide vs basal-bolus insulin alone in insulin-treated T2D during Ramadan
- BBn = 18reference
- BB+n = 18
- T1DMn = 18
- Outcome
- CGM metrics during Ramadan, BB+ vs BB
- Follow-up
- Ramadan (1-29 March 2025)
Methodological detailsCGM-based, matched 1:1 by age, baseline HbA1c and BMI
- CGM-based
- Matched 1:1 by age, baseline HbA1c and BMI
Main finding
As reported in the abstract
Reduction in incremental post-iftar AUC
≈61 %
By group
Observational data: associations, not effects.
Original publication
GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. Diabetes Res Clin Pract. Published 10 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →